Selected BCR-signaling antagonists in clinical development for CLL indications
| Target . | Agent . | Manufacturer . | Study phase . |
|---|---|---|---|
| BTK | Ibrutinib (PCI-32765) | Pharmacyclics/Janssen | 3 |
| CC-292 (AVL-292) | Celgene | 1b/2 | |
| GDC-0834 | Genentech | 1 | |
| ACP-196 | Acerta | 1 | |
| ONO-WG-307 | Ono | 1 | |
| PI3Kδ | Idelalisib (GS-1101, CAL-101) | Gilead Sciences | 3 |
| GS-9820 | Gilead Sciences | 2 | |
| AMG-319 | Amgen | 1 | |
| TGR-1202 | TG Therapeutics | 1 | |
| PI3Kδ/γ | IPI-145 | Infinity | 3 |
| Syk | GS-9973 | Gilead Sciences | 2 |
| Target . | Agent . | Manufacturer . | Study phase . |
|---|---|---|---|
| BTK | Ibrutinib (PCI-32765) | Pharmacyclics/Janssen | 3 |
| CC-292 (AVL-292) | Celgene | 1b/2 | |
| GDC-0834 | Genentech | 1 | |
| ACP-196 | Acerta | 1 | |
| ONO-WG-307 | Ono | 1 | |
| PI3Kδ | Idelalisib (GS-1101, CAL-101) | Gilead Sciences | 3 |
| GS-9820 | Gilead Sciences | 2 | |
| AMG-319 | Amgen | 1 | |
| TGR-1202 | TG Therapeutics | 1 | |
| PI3Kδ/γ | IPI-145 | Infinity | 3 |
| Syk | GS-9973 | Gilead Sciences | 2 |